Merck's small molecule cancer drug, acquired for over $1.3 billion, launches Phase 3 clinical trials in China
芊芊551
发表于 2024-7-24 18:35:33
216
0
0
According to the latest announcement on the Chinese Drug Clinical Trial Registration and Information Disclosure Platform, Merck's Class 1 oral drug MK-3543 (bomedemstat) for the treatment of primary thrombocytopenia has started Phase 3 clinical trials. Bomedemstat is an oral lysine specific demethylase 1 (LSD1) inhibitor, which Merck acquired from Imago BioSciences for approximately $1.35 billion in 2022.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- AbbVie Dual Anti Cancer New Drug Declares for Market in China
- Abbott announces the launch of its new women's health drug Fenyouning in China
- A sharp drop of 87%! Maserati will only sell over 30 units in China in September! Has the 'Sports Car Queen' fallen from grace?
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Nvidia expands in China against the trend, attracting talent and adding hundreds of R&D personnel in one year
- Apple is rumored to have preliminary discussions with Tencent and ByteDance to consider embedding their AI models into iPhones sold in China
- Sanofi's BTK inhibitor is declared for market in China
